Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

Toujeo^® versus degludec 100 U/mL in people with T1DM⁸

One Care study⁸

The first real-world study to compare 2nd-generation basal insulin analogues, Toujeo^® and degludec 100 U/mL, in people with T1DM, using continuous glucose monitoring.⁸

The primary endpoint of the One Care study was effectiveness of Toujeo^® versus insulin degludec 100 U/mL in terms of percentage of time in the predetermined glucose range (70-180 mg/dL). Time in range over the course of a full day was similar in both groups (52.4% for those receiving Toujeo^® versus 49.3% for the insulin degludec group. At night the time in range was significantly higher in the Toujeo^® group (52.4% versus 46.2%, p=0.0209).⁸

One Care was an observational, retrospective cohort, cross‑sectional, multicentre study of continuous glucose monitoring data in 199 adults with T1DM in Spain comparing the effectiveness (using percentage of time‑in‑range 70‑180 mg/dL over 14 consecutive days within a 4‑week period) and safety of Toujeo^® (insulin glargine 300 units/mL) versus degludec using continuous glucose monitoring in routine clinical practice.⁸

Limitations of the One Care study:⁸

• No randomisation
• No centralised laboratory
• No intensive control and monitoring of clinical practice
• The degludec 100 U/mL group presented a more severe course of disease (higher rates of retinopathy) compared with the Toujeo^® group

Diabetes Products